Cryptococcal Antigen Latex Agglutination Testing in Cats: Principles, Performance, and Clinical Application

Introduction

Feline cryptococcosis is a systemic fungal infection caused primarily by Cryptococcus neoformans and Cryptococcus gattii species complexes. The disease typically originates in the nasal cavity and can disseminate to the central nervous system, eyes, skin, and other organs [1]. Serological detection of cryptococcal capsular polysaccharide antigen has become a cornerstone of diagnosis and therapeutic monitoring in cats. The cryptococcal antigen latex agglutination test (CALAS) is a well-established method that detects glucuronoxylomannan (GXM), the major capsular polysaccharide of Cryptococcus species, in serum or other body fluids [2, 3]. This article provides a detailed technical review of CALAS in feline medicine, including its biophysical basis, diagnostic accuracy, clinical interpretation, and comparison with newer lateral flow assays.

Biophysical Principles of Latex Agglutination

The CALAS assay is based on the agglutination of latex particles coated with anti-cryptococcal antibodies when exposed to cryptococcal antigen in a sample. The reaction relies on the specific binding of GXM to polyclonal or monoclonal antibodies immobilized on the surface of uniform polystyrene latex beads. When sufficient antigen is present, cross-linking occurs between antibody-coated particles, forming visible clumps [3]. The test is typically performed in a serial dilution format to determine a semi-quantitative titer, defined as the highest dilution showing visible agglutination.

The assay requires pretreatment of serum samples with pronase (a mixture of proteases) to digest proteins that may cause non-specific agglutination or interference [4]. Pronase treatment reduces false-positive reactions by breaking down endogenous immunoglobulins and other serum proteins that could cross-link latex particles independently of cryptococcal antigen. After pronase digestion, the sample is heat-inactivated and then mixed with the latex reagent on a glass slide. Agglutination is read macroscopically after gentle rotation for a standardized period, typically 2 to 10 minutes [3, 4].

The sensitivity of the CALAS is influenced by the antigenic load, the avidity of the capture antibodies, and the absence of interfering substances. The test can detect GXM concentrations as low as 5 to 10 ng/mL in serum [3]. Because GXM is shed into the bloodstream during active infection, the CALAS titer correlates broadly with fungal burden, although the relationship is not linear and varies among individuals [1, 5].

Diagnostic Performance in Cats

The diagnostic accuracy of CALAS in cats has been evaluated in several studies. Medleau et al. [3] reported a sensitivity of 95% and a specificity of 100% in a cohort of 20 cats with confirmed cryptococcosis and 184 control cats. This study established the CALAS as a reliable reference standard for feline cryptococcosis diagnosis. Later work by Krockenberger et al. [2] in a larger sample of 129 cats found that the CALAS (used as the gold standard) had high sensitivity and specificity, although exact figures were not recalculated because it served as the comparator for a lateral flow assay. Wong et al. [6] used the CALAS as the reference standard for evaluating two lateral flow assays in a mixed population of dogs and cats, confirming its continued role as the benchmark.

The CALAS can yield false-negative results in cats with localized or early infections where antigen levels are below the detection threshold, or in cases of immune complex formation that sequesters antigen [4]. False-positive results are rare but can occur with pronase-resistant interfering substances, rheumatoid factor, or cross-reacting antibodies from other fungal infections [3, 4]. Interlaboratory variation in CALAS results has been documented, potentially due to differences in pronase pretreatment protocols, reagent lots, or subjective interpretation of agglutination endpoints [4].

Clinical Utility and Interpretation

CALAS testing serves multiple clinical purposes in feline cryptococcosis: initial diagnosis, assessment of disease severity, monitoring of treatment response, and determination of prognosis [1, 5]. A positive CALAS result in a cat with compatible clinical signs (e.g., nasal discharge, facial swelling, neurological deficits) strongly supports a diagnosis of cryptococcosis. The titer provides a semi-quantitative estimate of antigen burden; higher titers are generally associated with more extensive or disseminated disease [5].

Serial CALAS titers are used to monitor therapeutic efficacy. In a study of 35 cats treated with amphotericin B and fluconazole, Treekhunrungruang et al. [1] demonstrated that CALAS titers declined progressively over 12 months in parallel with clinical improvement. A declining titer indicates a favorable response, whereas a stable or rising titer suggests treatment failure, relapse, or inadequate drug penetration (e.g., into the central nervous system) [1, 5]. Jacobs et al. [5] also reported that sequential antigen titers were useful in predicting outcome; cats with persistently high titers had a poorer prognosis.

The CALAS titer should be interpreted in conjunction with clinical scoring systems and routine laboratory parameters. Treekhunrungruang et al. [1] used a six-domain clinical score (nasal, ocular, cutaneous, neurological, respiratory, and general) alongside CALAS titers and found that both measures improved over time. However, the CALAS titer may lag behind clinical resolution, and some cats maintain low positive titers for months after apparent cure [4, 5].

Comparison with Lateral Flow Assays

Lateral flow assays (LFAs) for cryptococcal antigen have been developed as point-of-care alternatives to CALAS. These immunochromatographic tests use monoclonal antibodies against GXM and produce a visible line on a test strip within 10 to 15 minutes [2]. Krockenberger et al. [2] compared an LFA with CALAS in 129 cats and found the LFA had a sensitivity of 92% and a specificity of 81% relative to CALAS. The lower specificity of the LFA (81%) meant that positive LFA results required confirmation by CALAS to avoid false-positive diagnoses [2].

Wong et al. [6] evaluated two commercial LFAs against CALAS in a combined cohort of dogs and cats. One LFA (IMMY) showed excellent performance with sensitivity of 95% and specificity of 100%, while the other (Dynamiker) had sensitivity of 100% but specificity of only 20%, indicating an unacceptably high false-positive rate [6]. These findings underscore that not all LFAs are equivalent, and CALAS remains the preferred confirmatory test when specificity is critical.

The CALAS offers advantages in quantitative titer determination and established clinical validation, whereas LFAs provide speed and simplicity for screening [2, 6]. A diagnostic algorithm incorporating both tests is presented below.

flowchart TD
    A[Cat with suspected cryptococcosis], > B{Perform LFA screening}
    B, >|Negative| C[Cryptococcosis unlikely; consider other diagnoses]
    B, >|Positive| D[Confirm with CALAS]
    D, >|Positive| E[Diagnosis confirmed; determine titer]
    D, >|Negative| F[Probable false-positive LFA; re-evaluate clinically]
    E, > G[Initiate antifungal therapy]
    G, > H[Serial CALAS monitoring every 1-3 months]
    H, > I{Titer declining?}
    I, >|Yes| J[Continue therapy until titer negative or low stable]
    I, >|No| K[Assess for treatment failure, resistance, or non-compliance]

Factors Affecting Test Results

Several pre-analytical and analytical factors can influence CALAS results. Sample quality is critical; hemolyzed, lipemic, or icteric sera may interfere with agglutination reading [3]. Pronase pretreatment is essential to reduce non-specific reactions, but the duration and temperature of pronase digestion must be standardized to avoid over-digestion that could degrade antigen [4]. The subjective nature of agglutination endpoint determination introduces inter-operator variability, particularly at low titers where weak agglutination may be difficult to distinguish from negative reactions [4].

Interlaboratory variation has been documented. McEwan and Sykes [4] reported discordant CALAS results between laboratories for the same feline patient, likely due to differences in pronase protocols and reagent sources. Clinicians should ideally use the same laboratory for serial monitoring to ensure consistency. The choice of latex reagent (e.g., polyclonal versus monoclonal antibodies) may also affect sensitivity and specificity, although most commercial CALAS kits use polyclonal antibodies raised against C. neoformans serotypes A and D [3].

Role in Treatment Monitoring and Prognosis

Serial CALAS titers are integral to managing feline cryptococcosis. A baseline titer should be obtained before initiating therapy. During treatment, titers are typically measured every 1 to 3 months [1, 5]. A fourfold or greater decline in titer is considered clinically significant and correlates with reduced fungal burden [1]. In the study by Treekhunrungruang et al. [1], median CALAS titers decreased from 1:256 at diagnosis to 1:8 after 12 months of therapy. Cats that achieved negative titers had the best outcomes, although some cats with low positive titers remained clinically normal [1, 5].

The CALAS titer also aids in detecting relapse. A rising titer after initial decline may indicate recrudescence of infection, often due to premature discontinuation of therapy or development of drug resistance [5]. In cats with neurological cryptococcosis, serum titers may not fully reflect central nervous system antigen burden, and cerebrospinal fluid CALAS testing may be warranted [5].

Limitations and Caveats

Despite its utility, CALAS has limitations. The test requires laboratory equipment (rotator, heat block) and trained personnel, making it less accessible in field settings compared to LFAs [2]. The turnaround time is longer (several hours including pronase treatment) than point-of-care tests. The semi-quantitative nature of the titer means that small changes (e.g., from 1:32 to 1:64) may not be clinically significant, and only fourfold or greater changes are considered reliable [1].

False-negative results can occur in cats with encapsulated Cryptococcus strains that shed less antigen, or in immunocompromised cats with low antigen production [3]. False-positive results, though rare, have been reported in cats with other systemic mycoses such as histoplasmosis or blastomycosis due to cross-reactive polysaccharides [3]. The test does not differentiate between C. neoformans and C. gattii, which may have implications for treatment and prognosis.

Frequently Asked Questions

What is the principle of the cryptococcal antigen latex agglutination test?

The test uses latex beads coated with anti-cryptococcal antibodies that agglutinate when exposed to cryptococcal capsular polysaccharide antigen (GXM) in a patient sample, producing visible clumps [3].

How should serum samples be prepared for CALAS?

Serum samples must be pretreated with pronase to digest interfering proteins, then heat-inactivated before mixing with the latex reagent [4].

What is the sensitivity and specificity of CALAS in cats?

Reported sensitivity is 95% and specificity is 100% in a controlled study of 20 infected and 184 non-infected cats [3].

Can CALAS be used to monitor treatment response?

Yes, serial CALAS titers are used to track therapeutic efficacy; a declining titer indicates a favorable response, while a rising titer suggests treatment failure or relapse [1, 5].

How does CALAS compare to lateral flow assays?

CALAS has higher specificity than most LFAs and provides a quantitative titer, making it the preferred confirmatory test. LFAs offer faster results and are suitable for screening but may have lower specificity [2, 6].

What causes false-positive CALAS results?

False positives are rare but can result from pronase-resistant interfering substances, rheumatoid factor, or cross-reacting antibodies from other fungal infections [3, 4].

Why is interlaboratory variation a concern?

Differences in pronase pretreatment protocols, reagent lots, and subjective interpretation of agglutination can lead to discordant results between laboratories [4].

What titer change is considered clinically significant?

A fourfold or greater change in titer (e.g., from 1:64 to 1:16) is generally considered significant [1].

References

[1] Treekhunrungruang S, Yurayart C, Thitiyanaporn C, et al. Clinicopathological Features, Treatment Outcome, and the Cryptococcal Antigen Latex Agglutination System Titer in Feline Cryptococcosis Treated with Amphotericin B and Fluconazole. Veterinary Sciences. 2025. URL: https://www.semanticscholar.org/paper/b69eeb2c7f0df7afcee471d83aa5168f0b4f11f9

[2] Krockenberger M, Marschner C, Martin PA, et al. Comparing immunochromatography with latex antigen agglutination testing for the diagnosis of cryptococcosis in cats, dogs and koalas. Medical Mycology. 2019. URL: https://www.semanticscholar.org/paper/b4aaaefba2cd314da46d84622b8da70884d8a60e

[3] Medleau L, Marks M, Brown J, et al. Clinical evaluation of a cryptococcal antigen latex agglutination test for diagnosis of cryptococcosis in cats. Journal of the American Veterinary Medical Association. 1990. URL: https://www.semanticscholar.org/paper/100be005c0f7e5f387b49a3e965efaea41813ac5

[4] McEwan S, Sykes J. Nasopharyngeal cryptococcosis in a cat: interlaboratory variation in cryptococcal antigen assay test results. JFMS Open Reports. 2022. URL: https://www.semanticscholar.org/paper/2bb22255503fa7bc099975da52fa74556e3bd9e2

[5] Jacobs G, Medleau L, Calvert C, et al. Cryptococcal infection in cats: factors influencing treatment outcome, and results of sequential serum antigen titers in 35 cats. Journal of Veterinary Internal Medicine. 1997. URL: https://www.semanticscholar.org/paper/7cdaa55fd126b61309fac19d07e5a3e9b0e81ef2 *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[6] Wong SA, Morton J, de Miranda LHM, et al. Diagnostic performance of lateral flow antigen tests versus latex agglutination for cryptococcosis in dogs and cats. American Journal of Veterinary Research. 2025. URL: https://www.semanticscholar.org/paper/3b11e00413d5aa93965315cd813cd8df3c6da4df